Melodia Therapeutics and Alivexis Ink Pact For Cathepsin C Inhibitor

Alivexis, Inc. furthermore, Melodia Therapeutics AG, an organization set up by Forty51 Endeavors, declared that they have forayed into an exclusive license agreement for the overall development, assembling, and commercialization of Alivexis' MDI-0151, a novel Cathepsin C inhibitor with top tier potential. MDI-0151 is an imaginative clinical candidate identified in Alivexis’ MOD-A discovery programme.

Melodia will quickly start IND-empowering exercises for MDI-0151 to get ready for a stage 1/phase 2a study in different refractory inflammatory sicknesses brought about by unnecessary enactment of neutrophils, for example, ANCA-related Vasculitis and a few other significant illnesses with regards to neutrophils. There is a significant unmet medical need for patients with these illnesses. In order to achieve clinical Proof of Concept in these indications, Alivexis and Melodia will will leverage their respective strengths in drug discovery research and development.

S. Roy Kimura,D., CEO of Alivexis, commented on the deal: “I am pleased to announce the signing of our licensing and clinical partnership with Melodia for our MOD-A Cathepsin C inhibitor programme. This event marks a significant milestone for Alivexis and serves as validation of our drug discovery R&D team and platform, our proprietary pipeline of discovery programs, and our business model involving the use of our cutting-edge platform to accelerate clinical candidate discovery for diseases with high unmet need. This is the first of many licensing and collaboration agreements that we anticipate from our maturing portfolio of IND-ready candidate molecules in our pipeline and our unique and proven discovery platform. We are confident that the Melodia team will be able to take our candidate molecule through clinical trials and ultimately help many patients in need suffering from chronic inflammatory diseases.”